Scientists at University of Utah Health made a discovery that could lead to a new way to treat Parkinson s disease and potentially stop its progression.
Early-Stage Drug Candidate Diminishes Deficits in Parkinson s Disease newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
University of Utah Health scientists have identified a molecule that slows cells’ production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson’s disease.
Targeting brain protein may lead to new therapeutic approaches for neurodegenerative disorders
Neurological disorders are the number one cause of disability in the world, leading to seven million deaths each year. Yet few treatments exist for these diseases, which progressively diminish a person s ability to move and think.
Now, a new study suggests that some of these neurological disorders share a common underlying thread. Staufen1, a protein that accumulates in the brains of patients with certain neurological conditions, is linked to amyotrophic lateral sclerosis (ALS), or Lou Gehrig s disease, along with other neurological disorders, including Alzheimer s, Parkinson s, and Huntington s disease, according to University of Utah Health scientists.